Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is MannKind Corp Finally a Buy?


Is MannKind Corp Finally a Buy?

MannKind Corporation (NASDAQ: MNKD) shares are up over 175% this month, and that's got anyone who's been paying attention to this troubled biotech wondering, "Can I still buy?" The company's massive short interest is likely behind a significant amount of the share-price rally, but the short covering was sparked by fundamental news regarding MannKind's inhalable insulin, Afrezza. So is this a stock investors should be buying?

MannKind's shares were trading below $1 as recently as August on the fear that a heavy debt load and anemic Afrezza sales would eventually result in the company's winding down.

IMAGE SOURCE: GETTY IMAGES.

Continue reading


Source: Fool.com

Sanofi S.A. ADR Stock

€52.50
0.000%
The Sanofi S.A. ADR price is unchanged compared to yesterday.
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Sanofi S.A. ADR.
As a result the target price of 55 € shows a slightly positive potential of 4.76% compared to the current price of 52.5 € for Sanofi S.A. ADR.
Like: 0
SNY
Share

Comments